ReviewToxins2016
Fibroblast Growth Factor-23-A Potential Uremic Toxin.
Review in Toxins, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 41 citations in OpenAlex.
- Effect of essential amino acid кetoanalogues and protein restriction diet on morphogenetic proteins (FGF-23 and Кlotho) in 3b-4 stages chronic кidney disease patients: a randomized pilot study.Clinical and experimental nephrology · 2018Trial
- A guide to uraemic toxicity.Nature reviews. Nephrology · 2026Review
- Fibroblast growth factor-23 remodels vascular extracellular matrix via glycosaminoglycan induction: implications for calcification in chronic kidney disease.Renal failure · 2025Article
- Benefits and Pitfalls of Uraemic Toxin Measurement in Peritoneal Dialysis.Journal of clinical medicine · 2025Review
- Vitamin D-Parathyroid Hormone-Fibroblast Growth Factor 23 Axis and Cardiac Remodeling.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025Review
- Review
- Clinical significance of serum CDC42 in the prediction of uremic vascular calcification incidence and progression.The Libyan journal of medicine · 2023Article
- The direct effect of fibroblast growth factor 23 on vascular smooth muscle cell phenotype and function.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Article
- Article
- Serum fibroblast growth factor-23 concentrations in young and mature adult cats with chronic kidney disease.Journal of feline medicine and surgery · 2022Article
- Classification of Uremic Toxins and Their Role in Kidney Failure.Clinical journal of the American Society of Nephrology : CJASN · 2021Review
- Extracellular Vesicles and Their Relationship with the Heart-Kidney Axis, Uremia and Peritoneal Dialysis.Toxins · 2021Review
- Association between serum fibroblast growth factor-23 concentration and development of hyperphosphatemia in normophosphatemic dogs with chronic kidney disease.Journal of veterinary internal medicine · 2021Article
- Uremic Toxins and Frailty in Patients with Chronic Kidney Disease: A Molecular Insight.International journal of molecular sciences · 2021Review
- Contribution of Gut Microbiota-Derived Uremic Toxins to the Cardiovascular System Mineralization.Toxins · 2021Review
- FGF23: A Review of Its Role in Mineral Metabolism and Renal and Cardiovascular Disease.Disease markers · 2021Review
- Uremic Toxins: An Alarming Danger Concerning the Cardiovascular System.Frontiers in physiology · 2021Review
- Chronic Kidney Disease as Oxidative Stress- and Inflammatory-Mediated Cardiovascular Disease.Antioxidants (Basel, Switzerland) · 2020Review
- Survival of patients treated with extended-hours haemodialysis in Europe: an analysis of the ERA-EDTA Registry.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2020Article
- FGF23, Biomarker or Target?Toxins · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibroblast growth factor-23 (FGF23) is a circulating member of the FGF family produced mainly by the osteocytes and osteoblasts that can act as a hormone. The main action of FGF23 is to lower phosphatemia via the reduction of urinary phosphate reabsorption and the decrease of 1,25(OH)₂-D generation in the kidney. In the course of chronic kidney disease (CKD), plasma FGF23 concentration rises early, most probably to compensate the inability of the deteriorating kidneys to excrete an adequate amount of phosphate. However, this comes at the cost of FGF23-related target organ toxicity. Results of clinical studies suggest that elevated plasma FGF23 concentration is independently associated with the increased risk of CKD progression, occurrence of cardio-vascular complications, and mortality in different stages of CKD. FGF23 also contributes to cardiomyocyte hypertrophy, vascular calcification, and endothelial dysfunction. The impact of FGF23 on heart muscle is not dependent on Klotho, but rather on the PLCγ-calcineurin-NFAT (nuclear factor of activated T-cells) pathway. Among the factors increasing plasma FGF23 concentration, active vitamin D analogues play a significant role. Additionally, inflammation and iron deficiency can contribute to the increase of plasma FGF23. Among the factors decreasing plasma FGF23, dietary phosphate restriction, some intestinal phosphate binders, cinacalcet (and other calcimimetics), and nicotinamide can be enumerated. Anti-FGF23 antibodies have also recently been developed to inhibit the action of FGF23 in target organs. Still, the best way to normalize plasma FGF23 in maintenance hemodialysis patients is restoring kidney function by successful kidney transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.